Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.250
+0.030 (2.46%)
At close: Mar 4, 2026, 4:00 PM EST
1.258
+0.008 (0.66%)
After-hours: Mar 4, 2026, 7:21 PM EST
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 5.75, with a low estimate of 4.00 and a high estimate of 7.50. The average target predicts an increase of 360.00% from the current stock price of 1.25.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Akebia Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +220.00% | Feb 25, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +220.00% | Feb 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +380.00% | Feb 6, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +300.00% | Dec 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +380.00% | Dec 2, 2025 |
Financial Forecast
Revenue This Year
240.54M
from 236.20M
Increased by 1.84%
Revenue Next Year
217.57M
from 240.54M
Decreased by -9.55%
EPS This Year
-0.08
from -0.02
EPS Next Year
-0.08
from -0.08
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 303.8M | 295.2M | |||
| Avg | 240.5M | 217.6M | |||
| Low | 148.3M | 183.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.6% | 22.7% | |||
| Avg | 1.8% | -9.5% | |||
| Low | -37.2% | -23.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.26 | 0.04 | |||
| Avg | -0.08 | -0.08 | |||
| Low | -0.35 | -0.18 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.